Patent · US Active

Solid dosage forms of vigabatrin

US10813898B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Orphelia Pharma · FR

Inventors

Charles Uzarama · Laval, CA
Patrick Gosselin · Laval, CA
Marie-Pierre Flament · Phalempin, FR

Key dates

Filing date	Mar 10, 2016
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Mar 10, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2072
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.